These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.
134 related articles for article (PubMed ID: 33601494)
1. Successful treatment with vedolizumab in an adolescent with Crohn disease who had developed active pulmonary tuberculosis while receiving infliximab. Choi S; Choi BS; Choe BH; Kang B Yeungnam Univ J Med; 2021 Jul; 38(3):251-257. PubMed ID: 33601494 [TBL] [Abstract][Full Text] [Related]
6. Safety, efficacy and pharmacokinetics of vedolizumab in patients with simultaneous exposure to an anti-tumour necrosis factor. Ben-Horin S; Ungar B; Kopylov U; Lahat A; Yavzori M; Fudim E; Picard O; Peled Y; Eliakim R; Del Tedesco E; Paul S; Roblin X Aliment Pharmacol Ther; 2018 Apr; 47(8):1117-1125. PubMed ID: 29446098 [TBL] [Abstract][Full Text] [Related]
8. Early vedolizumab trough levels at induction in inflammatory bowel disease patients with treatment failure during maintenance. Liefferinckx C; Minsart C; Cremer A; Amininejad L; Tafciu V; Quertinmont E; Tops S; Devière J; Gils A; van Gossum A; Franchimont D Eur J Gastroenterol Hepatol; 2019 Apr; 31(4):478-485. PubMed ID: 30672828 [TBL] [Abstract][Full Text] [Related]
9. Comparative efficacy and safety of vedolizumab and infliximab in ulcerative colitis after failure of a first subcutaneous anti-TNF agent: a multicentre cohort study. Hupé M; Rivière P; Nancey S; Roblin X; Altwegg R; Filippi J; Fumery M; Bouguen G; Peyrin-Biroulet L; Bourreille A; Caillo L; Simon M; Goutorbe F; Laharie D Aliment Pharmacol Ther; 2020 May; 51(9):852-860. PubMed ID: 32201971 [TBL] [Abstract][Full Text] [Related]
10. Low Rate of Drug Discontinuation, Frequent Need for Dose Adjustment, and No Association with Development of New Arthralgia in Patients Treated with Vedolizumab: Results from a Tertiary Referral IBD Center. Reinglas J; Gonczi L; Verdon C; Bessissow T; Afif W; Wild G; Seidman E; Bitton A; Lakatos PL Dig Dis Sci; 2020 Jul; 65(7):2046-2053. PubMed ID: 31813132 [TBL] [Abstract][Full Text] [Related]
11. Vedolizumab, an option in patients with inflammatory bowel disease intolerant to thiopurines and refractory to biological agents. Iborra M; Beltrán B; Maroto N; Navarro-Cortés P; Boscá-Watts M; Ferrer-Bradley I; García-Morales N; Sáez-González E; Hinojosa J; Mínguez M; Nos P Gastroenterol Hepatol; 2018 Nov; 41(9):535-543. PubMed ID: 30031573 [TBL] [Abstract][Full Text] [Related]
12. Extraintestinal Manifestations in Vedolizumab and Anti-TNF-Treated Patients With Inflammatory Bowel Disease. Dubinsky MC; Cross RK; Sandborn WJ; Long M; Song X; Shi N; Ding Y; Eichner S; Pappalardo B; Ganguli A; Wang A Inflamm Bowel Dis; 2018 Aug; 24(9):1876-1882. PubMed ID: 29668916 [TBL] [Abstract][Full Text] [Related]
14. Real-world clinical effectiveness and safety of vedolizumab and anti-tumor necrosis factor alpha treatment in ulcerative colitis and Crohn's disease patients: a German retrospective chart review. Helwig U; Mross M; Schubert S; Hartmann H; Brandes A; Stein D; Kempf C; Knop J; Campbell-Hill S; Ehehalt R BMC Gastroenterol; 2020 Jul; 20(1):211. PubMed ID: 32640990 [TBL] [Abstract][Full Text] [Related]
15. Development of Spinal Tuberculosis in an Adolescent With Crohn's Disease After Infliximab Therapy: A Case Report With Literature Review. Jung JH; Choi S; Kang Y; Cho DC; Lee SM; Park TI; Choe BH; Kim D; Kang B Front Pediatr; 2021; 9():802298. PubMed ID: 35223712 [TBL] [Abstract][Full Text] [Related]
16. Real-life efficacy of vedolizumab on endoscopic healing in inflammatory bowel disease - A nationwide Hungarian cohort study. Bor R; Fábián A; Matuz M; Szepes Z; Farkas K; Miheller P; Szamosi T; Vincze Á; Rutka M; Szántó K; Bálint A; Nagy F; Milassin Á; Tóth T; Zsigmond F; Bajor J; Müllner K; Lakner L; Papp M; Salamon Á; Horváth G; Sarang K; Schäfer E; Sarlós P; Palatka K; Molnár T Expert Opin Biol Ther; 2020 Feb; 20(2):205-213. PubMed ID: 31782939 [No Abstract] [Full Text] [Related]
17. Articular manifestations in patients with inflammatory bowel disease treated with vedolizumab. Dupré A; Collins M; Nocturne G; Carbonnel F; Mariette X; Seror R Rheumatology (Oxford); 2020 Nov; 59(11):3275-3283. PubMed ID: 32259251 [TBL] [Abstract][Full Text] [Related]
18. Soluble Mucosal Addressin Cell Adhesion Molecule 1 and Retinoic Acid are Potential Tools for Therapeutic Drug Monitoring in Patients with Inflammatory Bowel Disease Treated with Vedolizumab: A Proof of Concept Study. Paul S; Williet N; Di Bernado T; Berger AE; Boschetti G; Filippi J; Del Tedesco E; Nancey S; Flourie B; Roblin X J Crohns Colitis; 2018 Aug; 12(9):1089-1096. PubMed ID: 29860366 [TBL] [Abstract][Full Text] [Related]